Identification of tumor specific immunogenic mutations as potential immunotherapeutic targets

Identification of tumor specific immunogenic mutations as potential immunotherapeutic targets - CRG-TCR

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009977

Enrollment

800

Registered

2016-06-17

Start date

2014-10-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C18 C34 C56 C80.9 C82 C06 C19 C20 C10 C12 C13 C14 C83 C85

Interventions

Group 1: Tumor material of cancer pateints with a life exspectancy of at least 3 years will be tested for immunogenic mutations A) Identification of Tumor specific mutations 1. Identification of

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Histologically proven carcinoma, among others mainly carcinomas of the lung, colon and ovar or histologically proven lymphoma, age above 18 years, written informed consent

Exclusion criteria

Exclusion criteria: HIV, HBV, HCV, limited legal capacitiy

Design outcomes

Primary

Measure	Time frame
Identification of immunogenic mutations for development of T cell based immunptherapies at first diagnosis or relaps using molecular biological, protein biochemical and cell biological methods	—

Countries

Germany

Contacts

Public ContactAntonio Pezzutto

Charité Campus Benjamin Franklin

antonio.pezzutto@charite.de030-84452337

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026